No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors. Issue 4 (April 2017)

• Record Type: Journal Article
• Authors: Woestenberg, Petra J.; King, Audrey J.; van der Sande, Marianne A.B.; Donken, Robine; Leussink, Suzan; van der Klis, Fiona R.M.; Hoebe, Christian J.P.A.; Bogaards, Johannes A.; van Benthem, Birgit H.B.
• Is Part Of: Journal of infection. Volume 74:Issue 4(2017)
• Page Start: 393
• Page End: 400
• Publication Date: 2017-04
• Subjects: Human papillomavirus 6 -- Human papillomavirus 11 -- Condylomata acuminata -- Warts -- Vaccination -- Human papillomavirus vaccine, L1 type 16, 18 -- Prevention & control; Infection -- Periodicals; Bacterial Infections -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.905
• DOI: 10.1016/j.jinf.2017.01.007
• Languages: English
• ISSNs: 0163-4453

Abstract

Summary: Objectives: Data from a vaccine trial and from post-vaccine surveillance in the United Kingdom have suggested that the bivalent HPV-16/18 vaccine offers cross-protection against HPV-6/11 and protection against anogenital warts (AGW). We studied the effect of the bivalent vaccine on genital HPV-6/11 positivity and AGW in the Netherlands. Methods: We included all vaccine-eligible women from the PASSYON study, a biennial cross-sectional study among 16- to 24-year-old sexually transmitted infection (STI) clinic attendants. Vaginal self-swabs were analyzed for type specific HPV and AGW were diagnosed at the STI-clinic. Prevalence of HPV-6 and/or HPV-11 and AGW were compared between self-reported vaccinated and unvaccinated women by log-binomial regression analysis, adjusted for demographics and risk behavior. Results: Of the 1198 women included, 56% reported to be vaccinated at least once. Relative to unvaccinated women, the adjusted prevalence ratio (PR) for HPV-6/11 was 1.03 (95% confidence interval [CI] 0.74–1.43) for women vaccinated at least once. The crude PR for AGW was 0.67 (95% CI 0.22–2.07) for women vaccinated at least once. Adjustment did not change these results. Conclusions: We observed no cross-protective effect of the bivalent vaccine on genital HPV-6/11 positivity and a non-significant partially protective effect on AGW.